119 results about "Cytoskeleton" patented technology

The invention provides a preparation method of a recombinant collagen dressing, and belongs to the technical field of medical dressings. According to the technical scheme, stacked short sequences and continuous human collagen amino acid short sequences are repeatedly combined for multiple times to form recombinant collagen with specificity, and high similarity of the recombinant collagen with human collagen is ensured. On the basis, 4-FPBA is used as a cross-linking agent to respectively form a Schiff base bond responsive to pH and a boric acid ester bond responsive to glucose with CMCS and two kinds of HA with different molecular weights, and then the double-dynamic covalent cross-linked network adhesive hydrogel is synthesized. The triple-helix structure of the recombinant collagen is combined with a specific receptor on a cell membrane, and cell behaviors are regulated and controlled by inducing signal transduction through a cytoskeleton, so that skin microcirculation can be effectively improved, and a skin barrier can be repaired; the hydrogel dressing matrix has the effects of resisting inflammation, resisting oxidation, resisting bacteria, promoting healing and the like, the biological performance of the dressing is remarkably improved, and a better curative effect is achieved.

The invention discloses application of lupane derivatives in preparation of medicines for preventing and / or treating drug-induced deafness, and belongs to the field of biological medicines. The lupane derivative is represented by Chiisanoside, and experiments prove that the lupane derivative can activate the expression of Dock1 and PIP5K1A, inhibit the expression of Gelsolin and inhibit hair cytoskeleton actin instability induced by ototoxic drugs, and the lupane derivative has the advantages that the lupane derivative can be used for inhibiting the ototoxic drug-induced hair cytoskeleton actin instability, and the lupane derivative can be used for inhibiting the ototoxic drug-induced hair cytoskeleton actin instability; in addition, by activating expression of TGFBR2, SLC7A11 and GPX4 at the same time, hair cell ferroptosis induced by ototoxic drugs can be inhibited; further, the effects of preventing, treating or relieving the drug-induced deafness are exerted. The lupane derivative disclosed by the invention can be further developed into a multi-target therapeutic drug for preventing, treating and relieving drug-induced deafness.

The invention provides a myopia grading method driven by coupling of mechanical and morphological characteristics of corneal cells, and belongs to the technical field of myopia eye disease diagnosis and occurrence and development mechanisms based on artificial intelligence. The surface topography, Young modulus, adhesive power and other mechanical characteristics of corneal cells of patients with low, medium and high myopia are measured, corneal cell surface topography images obtained by an atomic force microscope are used as a cytoskeleton quantitative analysis data set, and edge extraction, brightness detection and multi-scale image segmentation methods are utilized to determine the surface topography of the corneal cells of the patients with low, medium and high myopia. The overall cytoskeleton distribution characteristics are quantified through the cytoskeleton region average complexity and cytoskeleton region average similarity, the method does not depend on dyeing, the tissue structure of the cytoskeleton can be evaluated more comprehensively, the method is suitable for more diversified cytoskeleton structures including complex clusters, a myopia grading model is established, and the myopia grading efficiency is improved. And a more direct cellular-level experimental basis is provided for the research on the occurrence and development mechanism of myopia.

The invention belongs to the technical field of cancer drugs, and particularly relates to a pancreatin-responsive bioactive peptide, nanofiber hydrogel prepared from the pancreatin-responsive bioactive peptide and application of the pancreatin-responsive bioactive peptide. The trypsin response-based bioactive peptide 1-Pept (the sequence of the trypsin response-based bioactive peptide 1-Pept is naphthylacetic acid-phenylalanine-glycine-tyrosine-lysine-cysteine-aspartic acid) and an anti-cancer drug adriamycin can be jointly assembled into 1-Pept / Dox nanofiber hydrogel, and a cytoskeleton can be destroyed by combining nanofibers with Dox; a series of cascade events resulting in cellular dysfunction are initiated, including mitochondrial damage, activation of apoptosis-associated proteins, and nuclear damage, thereby cooperatively causing tumor ablation. Compared with the existing single anti-cancer drug adriamycin, the in-vivo and in-vitro anti-cancer effect of the compound is obviously superior to that of the adriamycin pure drug, and the compound has obvious advantages in the aspect of resisting colon cancer.

The invention provides application of arabian jasmine flower lactone in preparation of a medicine for resisting senescence caused by microgravity. The arabian jasmine flower lactone can inhibit dissolution and / or deconstruction of F-actin caused by microgravity, stabilize cytoskeleton, and further inhibit or delay the aging process under microgravity. The invention also provides application of the arabian jasmine flower lactone in preparation of medicines for preventing and / or treating space diseases. The arabian jasmine flower lactone can inhibit organ and / or cell function decline caused by weightlessness in a space environment.

The invention discloses a tumor treatment molecule with a curative effect self-amplification function. Belongs to the technical field of biotechnology and new medicine, and comprises a peptide sequence Ac-Asp-Glu-Val-Asp-Cys (StBu)-Lys combined to a CBT part and a paclitaxel chemotherapy molecule connected to a lysine side chain. After the probe enters a tumor cell, the probe is specifically recognized by reducing glutathione highly expressed in the tumor cell, and an Ac-DEVDCK (PTX)-CBT structure is generated; then, a weak cell apoptosis phenomenon is initiated through a molecular grafted paclitaxel structure; the Ac-DEVD fragment is used as a high-specificity polypeptide substrate of cysteine-aspartic acid specific protease 3 which is necessary in a cell apoptosis pathway, and can be specifically cut by the cysteine-aspartic acid specific protease 3, so that the Ac-DEVDCK (PTX)-CBT is converted into CK (PTX)-CBT; then, CK (PTX)-CBT molecules are subjected to a CBT-Cys click reaction to form a cyclic dimer, and the cyclic dimer is self-assembled to form particles. According to the method, the affinity of the paclitaxel to the tubulin in the cytoskeleton is utilized, so that the tubulin in the cell is aggregated, the self-amplification effect of the curative effect of the cell is realized, and the cell is triggered to generate a pan-apoptosis effect.

The present invention relates to use of expression vectors and other compounds in methods to disrupt the LInker of Nucleoskeleton and Cytoskeleton (LINC) complex, uncoupling the nucleus from its linkage to the cytoskeleton, resulting in amelioration of diseases caused by one or more Lmna mutations, so-called laminopathies. More particularly, the invention relates to the expression of dominant negative SUN domain protein and / or dominant negative KASH domain protein to disrupt, for example, the LINC complex in cardiomyocytes for suppressing disease progression in dilated cardiomyopathy (DCM).

The invention belongs to the technical field of antibody preparation, and particularly relates to a monoclonal antibody aiming at human KRT19 and application thereof. The amino acid sequences of CDR1-3 on a light chain variable region of the monoclonal antibody are respectively shown as SEQ ID NO.3-5, and the amino acid sequences of CDR1-3 on a heavy chain variable region of the monoclonal antibody are respectively shown as SEQ ID NO.8-10. The monoclonal antibody provided by the invention can specifically recognize and accurately target KRT19 in cytoplasm, has good affinity in combination with KRT19, has strong anti-interference ability, effectively ensures that a detection signal is from a target antigen, has a high conformity degree between a detection result and an actual situation, and has good application prospects. A powerful tool is provided for high-sensitivity and high-precision detection of the KRT19 in tissues and / or cells, deep research on functions and regulation mechanisms of the KRT19 in cytoskeleton, epithelial tissue and tumor biology is facilitated, and the kit has important application prospects.

The present invention provides molecules that bind to cellular components or parts thereof (e.g., filaments or histones forming the cytoskeleton or nucleoskeleton) that are exposed to the extracellular environment upon cell death, which are specifically observed in diseased tissues, and simultaneously bind to target molecules on or in cells that act specifically in tissues where cell death is observed, such as diseased tissues, abnormal tissues, etc. The molecules of the present invention are useful as drugs that provide significant therapeutic or preventive effects while reducing side effects.

The invention provides a high gain detector (HGT) for sensing environmental ligand height change by cell integrin, a kit and application, the height of a double-stranded DNA probe is changed to 1-bp, 18-bp, 24-bp and 30-bp, and the length range is 0.5-10 nm. The two probes with different heights are subjected to a combined experiment to detect whether the cells can sense the height change of the ligand or not. According to the invention, the combination of 1bp and 18bp, the combination of 18bp and 30bp and the combination of 24bp and 30bp are utilized to find that the integrin can sense the height of the ligand and the sensitivity is 1-2nm. In addition, through experimental verification, the cell perception ligand height property has universality, and the cell skeleton hardness and the integrin state can adjust the integrin ligand height preference.

The invention belongs to the field of antitumor drugs and relates to a nano chelating agent capable of simulating a tumor epithelial-mesenchymal transition process and inducing ferroptosis as well as preparation and application of the nano chelating agent. The preparation method of the nano chelating agent is simple and low in cost, and specifically comprises the following steps: mixing and stirring MgSO4 and ethylenediamine tetraacetic acid disodium salt (EDTA) in a molar ratio of (0.5-2): 1, continuously stirring for 2-14 hours at the reaction temperature of 4 DEG C, and centrifuging to obtain the EDTA-Mg nano chelating agent. The EDTA-Mg nano chelating agent can destroy the connection between tumor cells, so that the adhesive force of the tumor cells is weakened, the cytoskeleton is remodeled, the polarity disappears, and the tumor cells are changed into a round cell form from an epithelial cell form, thereby realizing the simulation of the tumor epithelial-mesenchymal transition process. In addition, Fe < 2 + > of ferritin can be swept, and EDTA-Fe is formed. And EDTA-Fe reacts with rich H2O2 in the tumor to generate. OH with strong oxidizing property, so that mitochondria damage and lipid peroxidation are caused, and the tumor ferroptosis is induced.

The present invention relates to use of expression vectors and other compounds in methods to disrupt the Linker of Nucleoskeleton and Cytoskeleton (LINC) complex, uncoupling the nucleus from its linkage to the cytoskeleton, resulting in amelioration of diseases caused by one or more Lmna mutations, so-called laminopathies. More particularly, the invention relates to the expression of dominant negative SUN domain protein and / or dominant negative KASH domain protein to disrupt, for example, the LINC complex in cardiomyocytes for suppressing disease progression in dilated cardiomyopathy (DCM).

The present invention relates to a novel compound which modulates the function and differentiation of a cytoskeleton involved in pulmonary fibrosis and thus can be used for preparing a medicament capable of treating related diseases. It has been determined that: the novel compound according to the present invention or a pharmaceutically acceptable salt thereof has an effect of modulating actin polymerization required for cytoskeleton formation; and the expression of alpha-SMA and F-actin, which are main factors causing fibrosis, is effectively inhibited in human lung tissue-derived fibroblasts (MRC5). Furthermore, it has been determined that when activated macrophages are treated with the compounds, the level of inflammation of inflammatory cytokines caused by the macrophages is reduced. Therefore, the novel compound according to the present invention is expected to be effectively used in the prevention and treatment of diseases associated with pulmonary fibrosis as a preparation having an effect of inhibiting or reducing pulmonary fibrosis.

To provide compositions and methods for treating skin wounds, disorders and diseases.SOLUTION: The disclosure relates, in part, to a pharmaceutical composition comprising one or more polynucleotide species suitable for enhancing, increasing, augmenting, and / or supplementing the levels of Collagen alpha-1 (VII) chain polypeptide and / or lysyl hydroxylase 3 polypeptide and / or Keratin type I cytoskeletal 17 polypeptide in a subject. The disclosure also relates, in part, to pharmaceutical compositions and methods of use for providing prophylactic, palliative, or therapeutic relief of a wound, disorder, or disease of the skin in a subject, including a subject having, or at risk of developing, one or more symptoms of epidermolysis bullosa.SELECTED DRAWING: Figure 3

The invention belongs to the field of biotechnology and reproductive medicine, and relates to an application of a cytoskeletal regulatory factor ROCK2 in remodeling male reproductive hormone synthesis, the application is to prepare a preparation for regulating male reproductive hormone synthesis, the preparation is a gene silencing preparation, the active component of the preparation is a small interfering RNA molecule aiming at ROCK2, and the active component of the preparation is a small interfering RNA molecule aiming at ROCK2. By inhibiting expression and activity of ROCK2 in a target cell, enrichment of a cortex F-actin network in a cell cortex and formation of a ring structure are promoted, the level of a phosphorylated myosin light chain is up-regulated, and then the targeted transport efficiency of cholesterol in the cell to mitochondria is enhanced. According to the present invention, the structure is complete, the function is complete, the skeleton stability and the hormone synthesis function of the Redis cell are effectively maintained through the specific inhibition of the ROCK2 expression, the technical threshold and the time cost of the drug screening and evaluation are reduced through the established standardized detection system, and the controllability and the safety of the hormone regulation process are ensured.

The invention belongs to the cross technical field of cell engineering, nano-drugs and biological manufacturing, and particularly discloses a drug-loaded vesicle based on denucleated cells as well as a preparation method and application of the drug-loaded vesicle. According to the invention, a cell suspension and a cytoskeleton relaxant are co-incubated to relax an actin skeleton and weaken nucleoplasm connection; then loading the treated cell suspension on a multi-layer discontinuous density gradient centrifugal medium, realizing physical separation of cell nucleuses and cytoplasm through high-speed centrifugation according to buoyancy density difference, and collecting components of a specific interface to obtain high-purity denucleated cells with a complete membrane structure; then co-incubating the denucleated cells and ROS response type lipidosome (co-carrying therapeutic siRNA and a sound-sensitive agent Ce6) prepared in advance, so that the lipidosome is wrapped or anchored by a denucleated cell membrane; finally, the composite system is subjected to extrusion treatment through a microporous membrane, the drug-loaded vesicles uniform in particle size and stable in structure are obtained, and the drug-loaded vesicles are suitable for various application scenes such as anti-tumor treatment and RNA vaccine delivery.

The application belongs to the field of biological medicine, and provides application of miR-152 as a target in preparation of a drug for treating podocytopathy and the drug. Specifically, the application relates to application of miR-152 as a therapeutic target and / or a drug screening target in preparation of a drug for treating podocytopathy and a drug for treating FSGS nephropathy. The miR-152 inhibitor can inhibit high expression of miR-152 in kidney tissues of podocytopathy or FSGS nephropathy, inhibit down-regulation of synaptopodin protein, RhoA protein and 14-3-3 beta protein expression, protect stability of a cytoskeleton of a podocyte in kidney tissues, and delay progressive development of FSGS disease. The application provides a new therapeutic target for treatment of FSGS disease, and has important social and economic significance.

The invention relates to the technical field of cell culture, and particularly discloses a method for inducing somatic cells into pluripotent stem cells and the pluripotent stem cells. Comprising the following steps: sequentially carrying out induction culture on somatic cells by adopting a culture medium I, a culture medium II, a culture medium III and a culture medium IV to obtain the pluripotent stem cells, the I-IV culture medium adopts a DMEM high-glucose culture medium as a basic culture medium; each of the culture medium I and the culture medium II comprises the following components: a retinoic acid receptor stimulant, a glycogen kinase inhibitor, a TGF (Transforming Growth Factor) beta inhibitor, a selective inhibitor of cytoskeleton rearrangement related coiled-coil protein kinase, a receptor tyrosine kinase inhibitor, an SMO (Sequence Matrix Oxidase) stimulant, a Janus kinase 1 inhibitor, a Janus kinase 2 inhibitor and a Menin-MLL interaction inhibitor. The method for inducing the somatic cells into the pluripotent stem cells has the advantages of being low in cost, easy to operate, high in transformation efficiency and the like, and the human somatic cells can be efficiently and stably induced and recompiled into the pluripotent stem cells.

The invention discloses a combined medicine capable of effectively inhibiting tumor growth and metastasis. The combined drug for resisting tumor growth and metastasis comprises a Rho / ROCK inhibitor and a mitochondrial injury drug, wherein the mitochondrial injury drug is a chemotherapeutic drug coupled with a mitochondrial targeting ligand. The Rhoo / ROCK inhibitor destroys a cytoskeleton structure and blocks cytoskeleton-dependent mitochondrial transfer by inhibiting an Rhoo / ROCK signal channel, and the mitochondrial injury drug can selectively deliver a chemotherapeutic drug to mitochondria to cause mitochondrial injury. Compared with a single drug, the combined drug enhances damage to cytoskeletons and mitochondria, cuts off dynamic energy supply of the mitochondria to the cytoskeletons, makes up for the deficiency of tumor growth inhibition of the Rho / ROCK inhibitor, and has a good curative effect on tumor growth and metastasis resistance.

The invention discloses a composition for promoting tissue regeneration and injury repair and application thereof. Experiments find that macrophages are more easily polarized to M2 under mechanical stimulation, meanwhile, molecules CCM3 on adhesion spots are reduced, further molecular dynamics simulation finds that combination of CCM3 protein and paxilin protein is reduced and combination of FAK protein and paxilin protein is increased under certain mechanical stimulation, and meanwhile, cytoskeleton rearrangement is obvious. The invention clarifies the molecular mechanism of the influence of mechanical stimulation on cell behavior, and thus can be used for developing a novel regeneration treatment method.

This invention discloses the application of a PDLIM2 gene overexpression viral vector in the preparation of drugs for treating podocyte disease, wherein the nucleotide sequence of the PDLIM2 gene is shown in SEQ ID NO:1. This invention is the first to discover and verify the core role of the PDLIM2 gene in podocyte protection, confirming its significant downregulation in DKD and FSGS disease models, and demonstrating through functional experiments that PDLIM2 overexpression can effectively stabilize the podocyte cytoskeleton, inhibit apoptosis, and reduce proteinuria, thus establishing it as a key target gene for the treatment of podocyte disease. This invention is the first to intervene at the gene level in the core link of podocyte damage—cytoskeleton stability. By specifically upregulating the expression of PDLIM2 in podocytes, it directly enhances their intrinsic cytoskeleton support and anti-damage ability, achieving a fundamental shift in treatment strategy from "symptomatic support" to "causal repair."

The invention relates to the technical field of biomedical engineering, and particularly discloses a binary aggregate immune signal extraction method which comprises the following steps: screening out disease-related high-expression genes by utilizing a disease model, a normal model and a drug treatment model; an important protein molecule is screened based on a high-expression gene by using a nucleic acid-protein affinity analysis method; constructing a fusion vector based on cytoskeleton protein, important protein molecules and green fluorescent protein tracing; on the basis of fusion vectors of a disease model, a normal model and a drug treatment model, risk genes and possible downstream proteins associated with the agglomerates are identified through space group imaging, and meanwhile, the agglomeration process of the agglomerates is quantified. According to the method, the influence of the problems of state damage of the agglomerates, loss of spatial distribution information and the like is reduced, and immune microenvironment in-situ spatial organizational imaging and analysis of the evolution process of complex diseases are accurately realized.

The present invention relates generally to nano-scale lines and nano-electronic devices, which in some aspects can be embedded in biological structures, such as tissues, organoids, organs, organisms, and the like. For example, one aspect generally relates to a stretchable cytoskeleton that can be connected to an electrical circuit. In some cases, a biological structure may be formed around the scaffold and deformed when formed, thereby causing the cell scaffold to be embedded in the biological structure. In certain embodiments, the scaffold may be connected to an external device, for example, to determine a property (e.g., an electrical property) of the cellular scaffold, and / or to apply a stimulus (e.g., an electrical stimulus) to the biological structure. Other aspects of the invention generally relate to methods of making or using such cell scaffolds, kits comprising such cell scaffolds, biological structures comprising such cell scaffolds, and the like.

Hypomelanosis of Ito is a clinical term for patients with mosaic syndromes characterized by skin hypopigmentation and developmental disorders. The genetic causes of these rare diseases remain largely unclear. Here, we report that GNA13 is a new gene that causes Hypomelanosis of Ito. We identified an identical mutation in this gene in four unrelated patients exhibiting pigmentary mosaicism. In depth functional investigations revealed that this is an activatory mutation that alters the cytoskeleton and morphology of melanocytes via a hyperactivation of the RHOA / ROCK signalling pathway. Our results also indicate that this pathology does not necessarily originate from a decreased production of melanin, but can originate from a defect in melanosome transfer to keratinocytes due to cell shape alterations. Thus, our findings suggest for the first time a mechanism by which the clinical symptoms of patients with Hypomelanosis of Ito appear, and pave the path for new therapeutic approaches. Altogether, the present invention relates to a method for treating a patient suffering from hypomelanosis of Ito by administering a ROCK inhibitor and / or RHOA inhibitor.

The invention discloses pharmaceutical application of a P2Y11 specific inhibitor and a composition containing the P2Y11 specific inhibitor, and belongs to the technical field of biological medicine. The invention discloses application of NF157 in preparation of drugs related to treatment of HD5-promoted pathogenic infection for the first time. In the aspect of pathogen infection treatment, NF157 can specifically inhibit combination of P2Y11 and HD5, so that the effect that HD5 regulates cytoskeleton rearrangement to promote filamentous pseudopod generation is eliminated, and the NF157 becomes a key link for cutting off pathogen infection. By preventing the cells from generating filamentous pseudopod, the NF157 effectively blocks the capturing path of bacteria, and has a remarkable intervention effect on part of pathogens which are lack of adhesion devices and flagellum and are invaded by relying on cell pseudopod capturing.

The invention belongs to the technical field of biology, and particularly relates to a cell culture medium, a preparation method, cells obtained through culture and application, and the cell culture medium is prepared from 1-3 parts of hE-cad-Fc and 1-3 parts of hN-cad-Fc; cytoskeleton remodeling, glycolysis metabolism up-regulation, cell adhesion capability improvement, cell in-vitro amplification and proliferation capability improvement, cell stemness maintenance promotion, reduction of mechanical limitation of transcription factor nuclear translocation, substantial improvement of apoptosis and replicative aging of in-vitro long-term amplification of MSC, and substantial improvement of in-vitro long-term amplification of MSC. MSCs of the fifteenth generation obtained through hENFc energizing culture are free of tumorigenicity and chromatin mutation, clinical application standards of the MSCs are met, the novel energizing mesenchymal stem cells can be used for anti-inflammation, immune regulation and reversal of fibrosis of tissues such as skin, lung and liver, and the novel energizing mesenchymal stem cells have wide clinical application prospects.

This invention discloses the pharmaceutical applications of a P2Y11-specific inhibitor and compositions containing it, belonging to the field of biomedical technology. This invention discloses for the first time the use of NF157 in the preparation of drugs related to the treatment of HD5-induced pathogen infection. In combating pathogen infection, NF157 can specifically inhibit the binding of P2Y11 to HD5, thereby eliminating the role of HD5 in regulating cytoskeleton rearrangement and promoting filopodia formation, thus becoming a key link in interrupting pathogen infection. By preventing the formation of filopodia, NF157 effectively blocks the bacterial capture pathway, showing significant intervention effects on some pathogens that lack adhesion devices and flagella and rely on cellular pseudopodia capture for invasion.

The invention discloses an artificial cell and a preparation method thereof as well as a bionic tissue and a preparation method thereof, an aqueous dispersion of a negative electricity nanometer material is sprayed into an aqueous phase receiving bath containing a cationic polyelectrolyte and a surfactant through a gas-liquid shearing microfluidic technology, and one-step construction of an artificial cell membrane and a cytoskeleton is realized. According to the method, the internal skeleton enhanced artificial cell is constructed in a water phase by a one-step method by utilizing the electrostatic interaction of the negative electricity nano material and the cationic polyelectrolyte, and the method has the characteristics of convenience in preparation and excellent stability. By introducing different functional materials, multifunctional integration of the artificial cell can be realized. Meanwhile, the adhesion inducer is added, so that a bionic tissue can be further constructed, and the bionic tissue integrates excellent mechanical properties of the artificial cells and can bear disturbance to a certain degree without disintegration.

The invention provides a molecular self-assembly integrin patch for regulating and controlling mechanical signals of cells as well as a preparation method and application of the molecular self-assembly integrin patch, and an extracellular matrix (ECM) bionic cell patch is constructed through a molecular self-assembly technology. According to the patch, a laminin-derived integrin binding ligand is extended and self-assembled through an N-terminal aromatic amino acid to form a fibrous nano network, and the patch has controllable nano-scale ligand distribution, network viscoelasticity and stability, and can specifically activate integrin beta1 at the top end of MSC (mesenchymal stem cell), so that a mechanical signal is conducted from a cell membrane to a cell nucleus. The process coordinates cytoskeleton reconstruction, nuclear deformation and chromatin rearrangement, and finally drives the MSC to efficiently differentiate into neuron-like cells under the condition of no exogenous gene or chemical induction, so as to express nerve markers such as TUBB3 and present functional characteristics such as spontaneous calcium transient. The cell patch can be widely applied to nerve regeneration, tissue engineering, disease model construction and intelligent biological material development.